Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 9/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | ARAF | P10398 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239643 | 0.90 | CDK8 (0.39) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL3245548 | 0.86 | LCK (0.35) | — | |
| SCHEMBL6544374 | 0.84 | PARP10 (0.38) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL6544248 | 0.84 | PARP10 (0.40) | BRAFHDAC1SMN1; SMN2RAF1ARAF | |
| SCHEMBL27804098 | 0.84 | HSD17B1 (0.40) | SMN1; SMN2 | |
| SCHEMBL6543768 | 0.84 | MMP13 (0.43) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3238209 | 0.84 | PPARA (0.42) | MAP4K4HDAC1CYP17A1MAPKAPK2 | |
| SCHEMBL3244124 | 0.83 | MEN1 (0.42) | HPGDSMN1; SMN2NPY5RNPC1CRHBP | |
| SCHEMBL15930785 | 0.82 | ABL1 (0.35) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3244819 | 0.82 | CA2 (0.43) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-1022272-B1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | SANKYO CO (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | MAP4K4 3180/4885BRAF 311/4885HDAC1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.